| pubmed-article:9585867 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9585867 | lifeskim:mentions | umls-concept:C0287041 | lld:lifeskim |
| pubmed-article:9585867 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9585867 | pubmed:dateCreated | 1998-6-12 | lld:pubmed |
| pubmed-article:9585867 | pubmed:abstractText | Eprosartan is a nonpeptide angiotensin II receptor antagonist which has a high affinity for the AT1 receptor subtype. When administered at dosages of 400 to 800 mg/day (once or twice daily) for 13 weeks to patients with mild to moderate essential hypertension, eprosartan significantly reduced blood pressure compared with placebo. Eprosartan was at least as effective as enalapril 10 to 40 mg/day in a dose-titration study in patients with severe hypertension. Eprosartan is generally well tolerated; clinical trials have shown the drug to have a tolerability profile similar to that of placebo. As with other angiotensin II receptor antagonists, it does not cause cough. Eprosartan is not metabolised by the cytochrome P450 system and therefore has a low potential for drug interactions. | lld:pubmed |
| pubmed-article:9585867 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9585867 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9585867 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9585867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9585867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9585867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9585867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9585867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9585867 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9585867 | pubmed:month | May | lld:pubmed |
| pubmed-article:9585867 | pubmed:issn | 0012-6667 | lld:pubmed |
| pubmed-article:9585867 | pubmed:author | pubmed-author:BalfourJ AJA | lld:pubmed |
| pubmed-article:9585867 | pubmed:author | pubmed-author:McClellanK... | lld:pubmed |
| pubmed-article:9585867 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9585867 | pubmed:volume | 55 | lld:pubmed |
| pubmed-article:9585867 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9585867 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9585867 | pubmed:pagination | 713-8; discussion 719-20 | lld:pubmed |
| pubmed-article:9585867 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9585867 | pubmed:meshHeading | pubmed-meshheading:9585867-... | lld:pubmed |
| pubmed-article:9585867 | pubmed:meshHeading | pubmed-meshheading:9585867-... | lld:pubmed |
| pubmed-article:9585867 | pubmed:meshHeading | pubmed-meshheading:9585867-... | lld:pubmed |
| pubmed-article:9585867 | pubmed:meshHeading | pubmed-meshheading:9585867-... | lld:pubmed |
| pubmed-article:9585867 | pubmed:meshHeading | pubmed-meshheading:9585867-... | lld:pubmed |
| pubmed-article:9585867 | pubmed:meshHeading | pubmed-meshheading:9585867-... | lld:pubmed |
| pubmed-article:9585867 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9585867 | pubmed:articleTitle | Eprosartan. | lld:pubmed |
| pubmed-article:9585867 | pubmed:affiliation | Adis International Limited, Auckland, New Zealand. | lld:pubmed |
| pubmed-article:9585867 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9585867 | pubmed:publicationType | Review | lld:pubmed |
